Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type I-infected children

被引：11

作者：

Bergshoeff, AS

Fraaij, PLA

van Rossum, AMC

Verweel, G

Wynne, LH

Winchell, GA

Leavitt, RY

Nguyen, BYT

de Groot, R

Burger, DA

机构：

[1] Univ Med Ctr, Dept Clin Pharm, NL-6500 HB Nijmegen, Netherlands

[2] Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands

[3] Erasmus MC Sophia, Div Pediat Infect Dis & Immunol, Rotterdam, Netherlands

[4] Merck & Co Inc, West Point, PA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 05期

关键词：

D O I：

10.1128/AAC.48.5.1904-1907.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

So far, no pediatric doses for indinavir combined with ritonavir have been defined. This study evaluated the pharmacokinetics of 400 mg of indinavir/m(2) Combined with 125 mg of ritonavir/m(2) every 12 h (q12h) in 14 human immunodeficiency virus type 1-infected children. The area under the concentration-time curve from 0 to 24 h and the minimum concentration of drug in serum for indinavir were similar to those for 800 mg of indinavir-100 mg of ritonavir q12h in adults, while the maximum concentration of drug in serum was slightly decreased, with geometric mean ratios (90% confidence intervals in parentheses) of 1.1 (0.87 to 1.3), 0.96 (0.60 to 1.5), and 0.80 (0.68 to 0.94), respectively.

引用

页码：1904 / 1907

页数：4

共 25 条

[1] Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors [J].

Acosta, EP ;

Kakuda, TN ;

Brundage, RC ;

Anderson, PL ;

Fletcher, CV .

CLINICAL INFECTIOUS DISEASES, 2000, 30 :S151-S159

[2] Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load [J].

Arnaiz, JA ;

Mallolas, J ;

Podzamczer, D ;

Gerstoft, J ;

Lundgren, JD ;

Cahn, P ;

Fätkenheuer, G ;

D'Arminio-Monforte, A ;

Casiró, A ;

Reiss, P ;

Burger, DM ;

Stek, M ;

Gatell, JM .

AIDS, 2003, 17 (06) :831-840

[3]

Burger DM, 1998, ANTIVIR THER, V3, P215

[4] Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children [J].

Burger, DM ;

van Rossum, AMC ;

Hugen, PWH ;

Suur, MH ;

Hartwig, NG ;

Geelen, SPM ;

Scherpbier, HJ ;

Hoetelmans, RMW ;

Vulto, AG ;

de Groot, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :701-705

[5] Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy [J].

Fletcher, CV ;

Brundage, RC ;

Remmel, RP ;

Page, LM ;

Weller, D ;

Calles, NR ;

Simon, C ;

Kline, MW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1029-1034

[6] Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection [J].

Gatti, G ;

Vigano, A ;

Sala, N ;

Vella, S ;

Bassetti, M ;

Bassetti, D ;

Principi, N .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :752-755

[7] 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine [J].

Gulick, RM ;

Mellors, JW ;

Havlir, D ;

Eron, JJ ;

Meibohm, A ;

Condra, JH ;

Valentine, FT ;

McMahon, D ;

Gonzalez, C ;

Jonas, L ;

Emini, EA ;

Chodakewitz, JA ;

Isaacs, R ;

Richman, DD .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (01) :35-39

[8] Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [J].

Gulick, RM ;

Mellors, JW ;

Havlir, D ;

Eron, JJ ;

Gonzalez, C ;

McMahon, D ;

Richman, DD ;

Valentine, FT ;

Jonas, L ;

Meibohm, A ;

Emini, EA ;

Chodakewitz, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :734-739

[9] Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection - 100-week follow-up [J].

Gulick, RM ;

Mellors, JW ;

Havlir, D ;

Eron, JJ ;

Gonzalez, C ;

McMahon, D ;

Jonas, L ;

Meibohm, A ;

Holder, D ;

Schleif, WA ;

Condra, JH ;

Emini, EA ;

Isaacs, R ;

Chodakewitz, JA ;

Richman, DD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :35-41

[10] A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].

Hammer, SM ;

Squires, KE ;

Hughes, MD ;

Grimes, JM ;

Demeter, LM ;

Currier, JS ;

Eron, JJ ;

Feinberg, JE ;

Balfour, HH ;

Dayton, LR ;

Chodakewitz, JA ;

Fischl, MA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733

← 1 2 3 →